SUDA Pharmaceuticals Ltd

Receive alerts
Market Cap:
$13.46 m
0.04 AUD
52 weeks high
52 weeks low

SUDA Pharmaceuticals is a leader in reformulating drugs into an oral spray to increase bioavailability and to better meet patients' needs.


ZolpiMist™ is a US FDA approved, patented, cherry-flavoured, oro-mucosal spray formulation of zolpidem tartrate (marketed as tablets under the brand name of Ambien or Stilnox). Zolpidem tartrate is a non-benzodiazepine prescribed for the short-term treatment of insomnia characterised by difficulties with sleep initiation, as per Ambien’s approved indication.

ZolpiMist provides a convenient and easy-to-use alternative route of administration, by delivering a therapeutic dose with one or two actuations of the spray into the oral cavity.

ZolpiMist advantages may include reduced sleep patient convenience, and ease of use as it is administered without the need of water, unlike conventional tablets. Additionally, it may be used in patient populations experiencing difficulties in swallowing and/or suffering with gastrointestinal (GI) disorders that restrict the absorption of drugs via the GI mucosa.

Last updated 19th March 2020


Paul Hopper has international and ASX biotech capital markets experience and over 25 years’ experience in the medical, healthcare & life sciences sectors, particularly in immune-oncology and vaccines. He is the former Chairman of Viralytics Ltd (acquired by Merck for $500m in 2018), Founder and Director of Prescient Therapeutics Ltd, Founder of Imugene Ltd and Polynoma LLC, former Director of pSivida Corp, Somnomed Ltd and Fibrocell Science, Inc. Paul has deep experience in  corporate governance, risk and strategy.


David Phillips joined the Board as a Non-Executive Director in April 2018. He has 30 years of experience in the global healthcare industry, including Glaxo Wellcome, Cephalon Inc, Oxford Molecular Group Plc and SR One (GlaxoSmithKline’s corporate venture fund). David spent 12 years at Board level as Chief Business Officer of Argenta Discovery, The Automation Partnership and BioFocus PLC. David re-joined GlaxoSmithKline’s (GSK) SR One corporate venture arm in 2008 to pioneer a new function to incubate and spin-out technologies from GSK and in parallel investing in early-stage life science companies. David leads the Business Development activities. 


David was a senior audit partner with Ernst & Young from 1989 to 2017. From 2008 to 2013, David led the Capital Markets desk in Australia with responsibility for overseeing or reviewing all Australian cross border fundraisings. As an audit partner, David was involved in several high-profile businesses including Ramsay Health Care Ltd, John Fairfax Holdings and Commonwealth Bank of Australia and also was audit partner for the Australian operations of the leading US technology companies Hewlett Packard, Sun Microsystems and Oracle. David is currently a member of the Board and chairs the Audit, Risk and Finance Committee of MS Research Australia, the largest national not-for-profit body dedicated to funding and coordinating multiple sclerosis research in Australia.


Dr Baker was an Investment Manager with the leading Australian life science fund, BioScience Managers, where he was responsible for deal sourcing from networks, conferences, universities and research institutes. He also conducted due diligence to shortlist investment opportunities and played an active role in managing portfolio companies. Michael was a senior manager at Hexima Limited which specialises in developing agricultural and pharmaceutical products.

Dr Baker has a PhD in Biochemistry and was also awarded the prestigious Nancy Millis award for the most outstanding thesis for the Faculty of Science, Technology and Engineering, 2010. He was an Alexander von Humboldt Research Fellow at the University of Cologne with nine publications, one in the prestigious journal Science. He was also awarded an MBA at Melbourne Business School, where he was included in the Dean’s Honours List for being in the top 10% of graduating students. 


Dr. Worth has been working in the area of drug delivery systems for over 25 years at various international companies. As a development chemist, she liaised between companies in USA, UK and Asia to develop oral formulations of injectable peptide hormones. She has since been involved in the development of novel anticancer drugs and, most recently, topical pain relief formulations. Dr Worth has extensive experience in the setting up and running of GMP accredited laboratories and development of robust products suitable for GMP manufacturing. Dr. Worth has a PhD in Natural Product Chemistry from the University of Western Australia.


Dr Deborah Cooper is a Biotech professional with 25 years’ experience, expert in Cell Biology/Immunology, Clinical, Manufacturing, Product Development and Project Management. Deborah has 12 years in management of commercial technology organisations, including 7 years at the executive level. Deborah has worked for 4 years as an independent consultant to the Biotech sector, involved in managing product development, commercialisation strategy, regulatory submissions, grant applications, feasibility studies, GMP facilities, intellectual property management and placement of contract manufacturing, pre-clinical and clinical studies. Deborah has worked for 9 years in scientific research in private, not for profit and academic organisations; and 7 years studying at recognised tertiary institutions, achieving qualifications to the PhD level in the biological sciences arena.


Joseph Ohayon joined the company in July 2010 as the Chief Financial Officer and in March 2011 he took over the role of Company Secretary.  He has over 30 years experience in financial roles including 18 years within health-related industries. Joseph qualified as a Chartered Accountant in the UK and graduated with a Masters of Business Administration in International Business from Murdoch University in 2007.

Last updated 19th March 2020

Head Office

Level 1
Unit 12, 55 Howe Street
Osborne Park WA 6017

PO Box 1719
Osborne Park BC, WA 6916

General Contact

Ph: +61 8 6142 5555
E: info@sudapharma.com

Registered Office

Level 1, Unit 12, 55 Howe Street
Osborne Park WA 6017

Share Registry

Advanced Share Registry
110 Stirling Hwy
Nedlands WA 6009

PO Box 1156
Nedlands WA 6909

Share Registry Contact

Ph: 1300 113 258 or 9389 8033
F: 08 6370 4203
E: admin@advancedshare.com.au
W: www.advancedshare.com.au

Last updated 19th March 2020